Recently, a phase II trial (NCT02129075) showed that fms-like tyrosine kinase 3 (Flt3) ligand pre-treatment enhanced responses to dendritic cell (DC)-targeting vaccines in melanoma patients (148). The gene discussed is FLT3; the disease is melanoma.